ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in the Phase 1b clinical trial evaluating ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors.
“We look forward to the continued evaluation of ADCT-601, our AXL-targeting ADC, in advanced solid tumors after having established a manageable tolerability profile in our Phase 1a dose escalation trial,” said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. “AXL is an ideal target for an ADC approach because it is expressed in many solid tumors. In addition, the combination of ADCT-601 with gemcitabine is demonstrated to be synergistic in preclinical models of solid tumors.”
The Phase 1b open-label, dose-escalation and dose-expansion clinical trial evaluates the safety and tolerability of ADCT-601 as a single agent and in combination with gemcitabine in patients with selected advanced solid tumors. The first arm of the trial will enroll approximately 18 patients with sarcoma, a tumor resistant to current available cancer treatments in which AXL is overexpressed. For more information about the Phase 1b trial, please visit www.clinicaltrials.gov (identifier NCT05389462).